ILMNIllumina Inc. Nasdaq Global Select
Illumina Inc. 5200 Illumina Way San Diego CA, 92122 http://www.illumina.comIllumina Inc engages in life science tools and machines for analyzing genetic material. The company primarily engages in microarray and genome sequencing machines and disposables. It also provides sequencing services through its products.
- CEO: Francis A. DeSouza
- Employees: 6,200
- Sector: Healthcare
- Industry: Medical Diagnostics & Research
Latest news about the ILMN
- Biotech Veterans Troy Cox, Susannah Gray and Karen McGinnis Join Biosplice Therapeutics Board of Directors
SAN DIEGO, April 20, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of three independent directors to its board. New directors comprise Troy Cox, former CEO of Foundation Medicine, Susannah Gray, former EVP and CFO of Royalty Pharma Management, and Karen McGinnis, former VP and CAO of Illumina. “We are honored to have this caliber of experience and leadership join our new board at Biosplice,” said Osman Kibar, PhD, Founder and Executive Chairman of Biosplice. “Ms. Gray, Ms. McGinnis, and Mr. Cox bring invaluable insight to our company as we continue the buildout of our alternative splicing platform and navigate the final stages of clinical development for our lead osteoarthritis drug candidate, lorecivivint, and continue to develop our promising oncology and neurology pipelines.” Troy Cox led Foundation Medicine (NASDAQ: FMI), as President and Chief Executive Officer, through the acquisition by Roche for $5.3 billion in 2018. Prior to Foundation Medicine, he served as Senior Vice President and Officer at Genentech, where he led US BioOncology for a period of unprecedented growth to over $12 billion while accountable to help steer the Roche Genentech R&D portfolio. Before Genentech, Mr. Cox held executive and senior roles, including President UCB BioPharmaceuticals, Senior Vice President Sanofi-Aventis and diverse foundational roles at Schering-Plough. He also currently serves as a director of Zymeworks, Inc. (NYSE: ZYME), Sophia Genetics, LetsGetChecked, CM Life Sciences II (NASDAQ: CMIIU) and MassBio. Susannah Gray brings more than 30 years of biopharmaceutical experience, specifically in corporate finance and capital markets roles, most recently serving as Executive Vice President, Finance & Strategy of Royalty Pharma Management, LLC. Ms. Gray also spent 14 years as Executive Vice President and Chief Financial Officer of Royalty Pharma before retiring in 2019. Prior to joining Royalty Pharma, she had a 14-year career in banking, working in various capacities within high yield and structured finance departments of Chase Securities, Merrill Lynch and CIBC World Markets. Ms. Gray also serves as a director of Maravai LifeSciences (NASDAQ: MRVI) and 4D Molecular Therapeutics (NASDAQ: FDMT). Karen McGinnis has over 20 years of experience in executive operational and finance roles at international public companies. She most recently served as Vice President & Chief Accounting Officer of Illumina, Inc. (NASDAQ: ILMN), a leader in sequencing- and array-based solutions for genetic and genomic analysis. Earlier in her career, Ms. McGinnis served as Director, President and Chief Executive Officer, and previously Chief Financial Officer, of Mad Catz Interactive, Inc. (OTC: MCZAF), a global provider of innovative interactive entertainment products. Prior to joining Mad Catz, Ms. McGinnis served as Chief Accounting Officer of Cymer, Inc., a leading supplier to the semiconductor industry and, previously, Chief Accounting Officer for Insight Enterprises, Inc. Ms. McGinnis also currently serves as a director of Alphatec Holdings, Inc. (NASDAQ: ATEC) and AbSci, Inc. Learn more about Biosplice’s Board of Directors at https://www.biosplice.com/board-of-directors About BiospliceBiosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. Stemming from foundational discoveries in Wnt pathway modulation, Biosplice has elucidated novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative splicing. Alternative splicing is an essential biological mechanism that regulates the diversification of proteins in a cell, which, in turn, determines cell type and function. Biosplice’s target class governs the selection of tissue-specific mRNA splice sites, making them attractive, druggable targets within the cellular “command and control” center. Biosplice’s drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer’s disease to other degenerative conditions. Learn more at https://www.biosplice.com Corporate Contact: Erich HorsleyBiosplice Therapeutics, Inc.firstname.lastname@example.orgView More →
- EU to examine Illumina's $7.1 bln acquisition of Grail on antitrust grounds
EU antitrust regulators will examine Illumina Inc's proposed $7.1 billion acquisition of cancer test maker Grail Inc, the European Commission said on Tuesday, following a request from six countries on competition concerns. U.S. life sciences company Illumina announced last September that it would acquire Grail - which it previously owned before spinning it off as a separate business four years ago - by buying out investors including Amazon.com Inc founder Jeff Bezos. Illumina had remained the company's largest shareholder.View More →
- Illumina Remains Committed to GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test
Illumina disagrees with the European Commission’s Directorate-General for Competition’s decision to review Illumina’s acquisition of GRAIL.View More →
- 3 Biden Healthcare Stocks to Watch
The administration's focus on the Affordable Care Act, access to healthcare, and research may accelerate growth for these three stocks.View More →
- Is Illumina Still a Buy Without the GRAIL Acquisition?
Much to management's chagrin, the giant of gene sequencing hardware, Illumina (NASDAQ: ILMN), recently got a sharp rebuke in the form of an administrative complaint and federal lawsuit from the Federal Trade Commission (FTC) regarding its intended acquisition of GRAIL, a cancer screening company. Is Illumina going to be in trouble if the acquisition falls through?View More →
- Illumina, Inc. -- Moody's announces completion of a periodic review of ratings of Illumina, Inc.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Illumina, Inc.Global Credit Research - 14 Apr 2021New York, April 14, 2021 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Illumina, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review discussion held on 7 April 2021 in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. Since 1 January 2019, Moody's practice has been to issue a press release following each periodic review to announce its completion.This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.View More →
- The Big Questions for Illumina After Its Q1 Sneak Peek and 2021 Guidance
Illumina (NASDAQ: ILMN) delivered a pleasant surprise earlier this month with its revenue growth projected for the first quarter and for full-year 2021. In this Motley Fool Live video recorded on April 7, Motley Fool contributors Keith Speights and Brian Orelli talk about what the big questions for the gene sequencing giant are now after its Q1 sneak peek and full-year guidance. Keith Speights: Illumina, ticker there is I-L-M-N, just announced preliminary first-quarter revenue.View More →
- Labour steps up pressure over Cameron’s Greensill lobbying
The Labour party has called for a parliamentary inquiry into the Greensill scandal, as cross-party calls grew to strengthen the UK’s lobbying regime following revelations about the actions of former prime minister David Cameron. On Monday, Boris Johnson commissioned Nigel Boardman, a senior City lawyer, to investigate Cameron’s efforts to lobby senior ministers and government officials on behalf of Greensill Capital, the collapsed finance company. Last month Conservative MPs blocked a move by Labour to force the influential Treasury select committee to open an inquiry into the affair.View More →
- Can Illumina (ILMN) Keep the Earnings Surprise Streak Alive?
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.View More →
- How a Simple Blood Test Could Reduce Cancer Deaths
Liquid biopsies and genomic sequencing that track cancer-related DNA have spawned start-ups and produced eye-popping projections on Wall Street. The diagnostic technology is cutting edge, and the industry is very young.View More →
- This Unstoppable Stock Doesn't Pay a Dividend Yet, but It Could
Illumina (NASDAQ: ILMN) has never paid a dividend but has the cash flow to pay one. More importantly, it has a dominant position in the market for DNA sequencing technology that makes future profit growth inevitable. The Federal Trade Commission (FTC) is an important reason Illumina could have extra cash to distribute.View More →
- Could Illumina's Quest to Acquire GRAIL Fail?
In this Motley Fool Live video recorded on March 31, Motley Fool contributors Keith Speights and Brian Orelli discuss whether Illumina's quest to acquire GRAIL could ultimately fail. Illumina -- ticker there's ILMN -- learned yesterday, on Tuesday of this week, that the U.S. Federal Trade Commission is challenging its planned acquisition of GRAIL.View More →
- Illumina CEO says GRAIL deal is good for competition
The chief executive of life sciences company Illumina argued Thursday his company's deal to buy back GRAIL would lead to cheaper cancer tests rather than potentially pushing up prices as the government alleged in seeking to block the $7.1 billion transaction. Illumina said in a court filing this week that the Federal Trade Commission's request for a preliminary injunction should be denied because its arguments are "hopelessly speculative." "This acquisition provides huge benefits to people who may have cancer and don't know it," said CEO Francis deSouza.View More →
- BMY vs. ILMN: Which Stock Should Value Investors Buy Now?
BMY vs. ILMN: Which Stock Is the Better Value Option?View More →
- Company News for Apr 7, 2021
Companies in The News Are: ILMN, NVAX, MRNA, BP.View More →
- Why Illumina Stock Fell 12.6% in March
Shares of Illumina (NASDAQ: ILMN) dipped 12.6% in March, according to data from S&P Global Market Intelligence. The stock lost ground due to negative analyst coverage and a challenge to its acquisition of liquid-biopsy specialist Grail. Barclays analyst Luke Sergott published a note initiating coverage on Illumina stock on March 2.View More →
- Illumina Stock Pops As Covid Surveillance Helps Drive Unexpected Beat And Raise
Illumina stock gapped up Tuesday after the company preannounced 26% revenue growth in the first quarter and boosted its full-year guidance. Analysts were split on the preannouncement.View More →
- FTC’s Challenge of Illumina Is a Boost for Rivals in Cancer Test Race
Stocks of companies seeking to develop multicancer screening tests rose after regulators objected to Illumina's deal to acquire the leader in that race, Grail.View More →
- Why Illumina Stock Just Jumped 10%
Shares of Illumina (NASDAQ: ILMN) -- the self-proclaimed "global leader in DNA sequencing" -- were rocking Tuesday afternoon, up a solid 9.5% at 12:15 p.m. EDT after the company announced record orders and superb sales for the first quarter of 2021. In yesterday's after-market announcement, Illumina told investors it expects to report $1.4 billion in orders, up 28% year over year; and $1.1 billion in first-quarter revenue, up 26% year over year. The company also updated full-year revenue guidance to predict that sales will grow between 25% and 28%.View More →
- Illumina’s Gene-Sequencing Business Is Rebounding. It’s Girding for an Antitrust Fight.
Illumina's gene-sequencing business has recovered from the Covid-19 slowdown. Meanwhile, the company is fighting regulators to close an acquisition that would bring a huge growth opportunity.View More →